Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-guided therapy in newly diagnosed advanced Hodgkin lymphoma
ACTRN12610000927022Phase 3Completed
- Sponsor
- University College London
- Start
- Sep 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, bleomycin, vinblastine, dacarbazine, cyclophosphamide and 6 more in Hodgkin lymphoma (HL) (4 arms), sponsored by University College London. Primary endpoint: progression-free survival. Started Sep 2010; status: completed.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazinecyclophosphamide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on ACTRN12610000927022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000927022.